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Abstract
Low-Se status may be associated with a higher risk of notably advanced prostate cancer. In a Danish population with a relatively low Se intake, we
investigated the association between pre-diagnostic Se status and (1) the risk of total, advanced and high-grade prostate cancer and (2) all-cause and
prostate cancer-speciﬁc mortality among men with prostate cancer. Within the Danish ‘Diet, Cancer and Health’ cohort, including 27179 men, we
identiﬁed 784 cases with incident prostate cancer through 2007. Each case was risk set-matched to one control. Two-thirds (n 525) of the cases
had advanced disease at the time of diagnosis, and among these 170 had high-grade disease; 305 cases died (n 212 from prostate cancer) during
follow-up through 2012. Plasma Se was not associated with total or advanced prostate cancer risk, but higher Se levels were associated with a lower
risk of high-grade disease (HR 0·77; 95% CI 0·64, 0·94; P=0·009). In survival analyses, a higher level of plasma Se was associated with a lower risk of
all-cause (HR 0·92; 95% CI 0·85, 1·00; P=0·04), but not prostate cancer-speciﬁc mortality. Higher levels of selenoprotein P were associated with a
lower risk of high-grade disease (HR 0·85; 95% CI 0·74, 0·97; P=0·01), but not with the risk of or mortality from advanced prostate cancer.
In conclusion, levels of plasma Se and selenoprotein P were not associated with the risk of total and advanced prostate cancer, but higher levels of
these two biomarkers were associated with a lower risk of high-grade disease.
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Se, an essential trace mineral, has been suggested to possess
cancer-protective effects(1). The cancer-protective mechanisms
of Se may be related to its incorporation in the amino acid
selenocysteine in selenoproteins(2), and they include reduction
of DNA damage and oxidative stress, enhancement of immune
response and induction of apoptosis(3–5).
Dietary Se intake varies worldwide and is highly dependent
on soil Se content(6). The variation in human dietary intake is
reﬂected in the global variation in blood Se levels(7), with
relatively low levels observed in Europe and higher levels in the
USA(8,9). These geographical differences in Se levels have been
in focus in the discussion of Se and its relation to prostate
cancer risk(10). A recent report from the World Cancer Research
Fund International concluded a ‘limited-suggestive’ relationship
between ‘low plasma Se concentrations’ and higher risk of
prostate cancer(11). A systematic review and meta-analysis by
Hurst et al.(10), published as a part of the update report by
World Cancer Research Fund International, showed an inverse
association between plasma/serum Se and especially advanced
prostate cancer. On the basis of available results, which also
included studies determining Se status by toenail Se
concentrations, the authors also speculated that a U-shaped
association might exist between Se levels and prostate
cancer risk(10).
The evidence from randomised clinical trials is
conﬂicting(1,10). The Selenium and Vitamin E Cancer Prevention
Trial found no effect of 200 µg Se supplementation/d on
incidence of prostate cancer in a high-Se US population
(median baseline serum level approximately 136 ng/ml)(12).
A post hoc analysis revealed, however, that Se supplementation
increased the risk of high-grade prostate cancer in men with the
highest baseline Se levels(13). The smaller Nutritional Prevention
of Cancer (NPC) trial also supplemented the participants
with 200 µg Se/d, but it was conducted in a US population
with lower baseline Se status (mean plasma Se approximately
115 ng/ml)(14). In this study, Se supplementation was related
to decreased prostate cancer risk only in the subgroup of men
with baseline Se levels <123 ng/ml(15).
Abbreviations: HR, hazard ratio; PSA, prostate-speciﬁc antigen.
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Results from the US Third National Health and Nutrition
Examination Survey (NHANES III) are also compatible with a
differential effect of Se supplementation on prostate cancer risk
according to baseline Se status(16). Study subjects in the
NHANES III population had mean serum Se levels of 125 ng/ml,
and in this moderate Se level US population a non-linear
association was suggested for all-cause and cancer mortality
with higher risk at lower Se levels(16).
Various biological markers of Se status have been considered for
assessing Se exposure(17,18). One biomarker is selenoprotein P,
which is the major selenoprotein in plasma(19–21). The primary role
of this selenoprotein is to transport and deliver Se to tissues(19–21).
Selenoprotein P is expected to reach maximal concentration at
plasma Se levels ranging from 90 to 125ng/ml(22,23), which is not
reached in low-Se-status populations. Thus, selenoprotein P
concentrations may be regarded as a measure of the functional Se
status(17). The association between selenoprotein P and prostate
cancer risk has previously been studied in a low-Se-status
population; however, they found no association(24).
Overall, the results from observational studies and randomised-
controlled trials suggest that there may be a narrow window of
basic Se status associated with a lower risk of clinically advanced
prostate cancer(10) and thus death from prostate cancer. An
evaluation of this association will beneﬁt from measurements of
different biomarkers of Se, as they represent different biological
aspects of Se status: short-term exposure (plasma Se)(25) and
functional Se status (selenoprotein P)(17).
Denmark represents a low-Se region with mean serum/plasma
levels of Se approximately 90–100ng/ml(26,27), and consequently
the Danish population is likely to have a suboptimal Se status. Thus,
we hypothesised that low Se concentrations in blood among Danes
are associated with a higher risk of prostate cancer, as well as
higher prostate cancer-speciﬁc and all-cause mortality. In a
case–control study nested within the Danish prospective ‘Diet,
Cancer and Health’ cohort, we examined the association between
pre-diagnostic blood Se, measured as plasma Se or selenoprotein P,
and risk of total, advanced and high-grade prostate cancer.
Furthermore, we evaluated the association between pre-diagnostic
Se levels and all-cause and prostate cancer-speciﬁc death among
men diagnosed with prostate cancer.
Methods
Study population
This nested case–control study was conducted within the
Danish population-based prospective cohort ‘Diet, Cancer and
Health’. Between December 1993 and May 1997, 80 996 men
aged 50–64 years and resident in the greater Copenhagen and
Aarhus areas were selected from the Danish Central Population
Registry and invited to participate in the cohort. All participants
were born in Denmark and had no previous history of cancer.
A total of 27 179 men were enroled, corresponding to 34% of
those invited. The cohort has been described in details
previously(28). The study protocol was approved by the regional
ethics committees on human studies in Copenhagen
and Aarhus and by the Danish Data Protection Agency.
All participants provided written informed consent.
Data collection
At cohort enrolment, all participants completed a questionnaire
on social and lifestyle factors. From this questionnaire, we
obtained information about education (years of education after
secondary school: low, medium, high), smoking status (never,
former, current), smoking duration (years), current tobacco use
(g/d) and participation in sport (yes/no).
At the study centre, a nonfasting 30-ml blood sample (col-
lected in citrated and plain Venojects tubes) was taken from all
participants, and plasma, serum, lymphocytes and erythrocytes
were isolated. All samples were processed and frozen within 2 h
at −20°C. Within the day of blood sampling, all samples
were stored in liquid N2 vapour at a maximum of −150°C.
Anthropometrical measurements such as weight and height
were carried out by professional staff members; BMI was
calculated as weight (kg) divided by height squared (m2).
Ascertainment of diagnosis and mortality
Information on vital status and emigration was obtained
through linkage to the Central Population Registry using unique
personal identiﬁcation numbers. Information on cancer occur-
rence among cohort members was obtained through record
linkage to the Danish Cancer Registry, which collects
information on all cases of cancer diagnosed(29). Each cohort
member was followed up for prostate cancer occurrence from
date of enrolment until the ﬁrst date of diagnosis of any cancer
(except for non-melanoma skin cancer), date of death or
emigration or 31 December 2007, whichever came ﬁrst. Loss to
follow-up was a minor problem (0·02%). We identiﬁed 911
cases of primary prostate cancer during the follow-up period
(1993–2007). Of these, 127 were excluded because of lack of
blood sample (n 40), failure in Se measurements (n 52), missing
data on potential confounders (n 10) or implausible value (n 1).
Participants with missing information on selenoprotein P also
had their plasma Se concentration excluded from the analyses
to ensure that data were comparable, and ﬁnally incomplete
case–control pairs were excluded (n 24), leaving 784 complete
case–control pairs for the statistical analyses.
Each case of prostate cancer was matched 1:1 with a male
control participant using a risk set sampling from eligible cohort
members who were alive and free of cancer and had the same
length of time from baseline to diagnosis. The matching criteria
were age at blood collection (±6 months), time of day of
blood collection (±1 h) and fasting status (time since last meal:
<3, 3–5, >5 h). The half-life of Se in plasma is approximately
8 h(30); matching by time of day and fasting status was done to
minimise error by this factor.
By medical record review, we obtained information on
stage and Gleason grade for the prostate cancer cases, as well
as the underlying reason for diagnosis (urological symptoms,
prostate-speciﬁc antigen (PSA) level at diagnosis or Gleason
score at biopsy). Information on clinical TNM (tumour/nodes/
metastasis) stage was extracted from the Danish Cancer Reg-
istry, which holds information on TNM stage since 2004; for
cases diagnosed before 2004, extent of disease was categorised
as ‘localised’, ‘regional’ or ‘distant’. We deﬁned ‘advanced
1670 M. Outzen et al.
http:/www.cambridge.org/core/terms. http://dx.doi.org/10.1017/S0007114516000726
Downloaded from http:/www.cambridge.org/core. DTU Library - Tech Info Ctr of Denmark, on 18 Oct 2016 at 12:03:17, subject to the Cambridge Core terms of use, available at
prostate cancer’ as ≥T3 or Gleason score ≥ 7 or N1 or M1, or
‘regional’/‘distant’ extent of disease or PSA> 15. We deﬁned
‘high-grade prostate cancer’ as Gleason score ≥8.
Information on precise date of death and cause of death was
obtained by linkage to the Danish Causes of Death Registry(31).
The case population of 784 men with a primary diagnosis of
prostate cancer was followed up from date of diagnosis until the
date of death or emigration or end of follow-up (31 December
2012). Of these, 305 died during follow-up, 212 of them from
prostate cancer.
Chemical analyses
Se was determined by mixing 200 µl of plasma with 5ml of an
aqueous diluent containing 0·5% v/v Triton X-100 (surfactant),
10% v/v ethanol and 1% v/v nitric acid. The Se concentration in
the diluted plasma samples was determined by inductively
coupled plasma MS (6100 ICP-DRC-MS; Perkin-Elmer-Sciex) for
detection of Se as 78Se against an external standard curve
prepared in the same diluent. Diluted samples, standards and
blanks were spiked at 10 ng/ml with 93Nb, which was used as
an internal standard. On the basis of double determinations of
5% of all samples, the precision of the analyses was estimated
at 2·0% (relative standard deviation; RSD), and the accuracy
was assured by repeated analysis of the BCR 637 Human Serum
certiﬁed reference material (CRM) (IRMM) throughout the
entire analytical campaign. The mean value found was 84
(SD 3) ng Se/ml (n 85), which coincided with the certiﬁed value
of 81 (SD 7) ng Se/ml. The limit of detection (LOD) for Se in the
undiluted plasma samples was 3 ng Se/ml.
The content of selenoprotein P in the selected subset of the
plasma samples was determined as described in detail by
Outzen et al.(32). In brief, the undiluted samples were injected
onto a heparin-afﬁnity HPLC column, which selectively retained
selenoprotein P. Following an elution step with a solution of
heparin at 500 units/ml, the selenoprotein was detected by
ICP-DRC-MS as 80Se and quantiﬁed by post-column isotope
dilution by adding a calibrant solution enriched in 77Se via a
T-piece. The ICP-MS was set to monitor the two Se isotopes.
Precision of the analyses was estimated from double
determinations of plasma samples (n 56) across the entire
analytical campaign, and it was estimated at 2·0% (RSD). The
mean values for selenoprotein P quantiﬁed in the same
CRM were 50 (SD 3) ng Se/ml (n 61) and amounted to 62% of all
Se in the CRM. Because selenoprotein P has not been certiﬁed
in this or any other CRM, evaluation of the analytical accuracy
was not possible. The LOD for selenoprotein P was estimated at
6 ng Se/ml. All values of plasma Se and selenoprotein P were
above the LOD.
PSA levels in serum were measured with the Architect PSA
chemiluminescent microparticle immunoassay on the Architect
i2000SR system (Abbott Diagnostics).
Statistical analyses
Associations between plasma Se and selenoprotein P and risk
of prostate cancer were estimated by conditional logistic
regression stratiﬁed by case–control pair. OR and 95% CI were
estimated from both crude (conditioned on the matching
factors: age at blood collection, time of day of blood collection
and fasting status) and multivariable models. Analyses were
conducted for total prostate cancer (plasma Se) and separately
for advanced and high-grade prostate cancer (plasma Se and
selenoprotein P).
The multivariable adjusted analyses included factors of potential
relation to prostate cancer risk and/or blood Se levels, including
BMI (continuous), education (low, medium, high), smoking status
(never, former, current), smoking duration (continuous), smoking
frequency (continuous) and participation in sport (yes/no). Effect
measure modiﬁcation by BMI and smoking was evaluated in the
adjusted models for total and advanced prostate cancer using the
likelihood ratio test statistics. These factors were considered to be
involved in oxidative stress conditions and were therefore
considered potential effect modiﬁers(33).
In the adjusted analyses on prostate cancer risk (total and
advanced prostate cancer), we evaluated whether the association
differed by time from baseline to diagnosis (≤6 and >6 years) or by
PSA levels at baseline (≤4 and >4ng/ml). These sub-analyses were
not performed for high-grade disease because of limited statistical
power regarding this endpoint.
The associations between plasma Se and selenoprotein P and
all-cause and prostate cancer-speciﬁc mortality among the prostate
cancer cases were estimated by Cox proportional hazards models
with follow-up (from date of diagnosis) as the underlying
time-scale and stratiﬁcation by age at diagnosis in 5-year intervals.
Follow-up time was included as a time-dependent variable to
account for minor violations of the proportional hazard
assumption. From this model, hazard ratios (HR) and 95% CI were
estimated. The associations were estimated among all cases
regardless of stage or grade of disease. The major part of prostate
cancer-speciﬁc deaths occurred in cases with advanced disease.
Associations were evaluated without and with adjustment for the
above-mentioned potential confounders. Furthermore, potential
effect modiﬁcation on a multiplicative scale by BMI and smoking
was evaluated.
The OR and HR for Se concentration were estimated as
categorical (per quartile) and linear (per increment of
concentration) variables. Quartile cut-off points were based on the
distribution in controls (risk analyses) and prostate cancer cases
(mortality analyses). The units used for estimation in the linear
analyses corresponded approximately to the interquartile range of
plasma Se (increment of 10ng/ml) and selenoprotein P (increment
of 5ng Se/ml) levels among control participants (risk analyses) and
prostate cancer cases (mortality analyses). Before including these
two Se variables into the models, the linearity of the association
was evaluated graphically by linear splines with 3 knots placed at
the quartile cut-off points for exposure distribution among cases(34).
Linearity of the quantitative variables included in the adjusted
model (BMI, smoking duration, smoking frequency) was evaluated
in the same way. None of the associations showed signs of
deﬂection or threshold values.
Correlation between plasma Se and selenoprotein P was
evaluated in the 525 controls using Pearson’s correlations.
Two-sided 95% CI for the OR and HR were calculated. The
procedure PHREG in the SAS software package (release 9.3;
SAS Institute) was used for the statistical analyses.
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Results
Baseline characteristics of the total (n 784), advanced (n 525)
and high-grade prostate cancer case groups (n 170) and the
control group (n 784) are shown in Table 1. Cases had a longer
education, whereas smoking habits, physical activity and
plasma Se levels were similar among cases and controls. The
median plasma Se concentrations were approximately 79 ng/ml
in all four groups. The overall range of plasma Se of approxi-
mately 60–105 ng/ml conﬁrmed the low-Se status of the entire
population. The median concentration of selenoprotein P was
approximately 50 ng Se/ml in all groups.
The level of plasma Se was not associated with total or advanced
prostate cancer risk (Table 2). Adjustment for potential confounders
did not inﬂuence the OR estimates materially. Similarly, no
substantial differences in OR were seen in analyses stratiﬁed by
duration of follow-up (≤6 v. >6 years) or by PSA levels at baseline
(≤4 v. >4ng/ml). For high-grade disease, higher plasma Se
levels were associated with a lower risk in both the minimally
adjusted (HR 0·83; 95% CI 0·71, 0·98; P=0·03) and in the
confounder-adjusted model (HR 0·77; 95% CI 0·64, 0·94; P=0·009).
In the analyses of selenoprotein P among cases with advanced
prostate cancer (Table 3), we observed no associations, irrespective
of confounder control, duration of follow-up or baseline PSA levels.
Table 1. Characteristics of total, advanced and high-grade prostate cancer cases, and their matched controls
(Medians and 5th–95th percentiles; numbers and percentages)
Case–control risk analysis
Controls Total cases Advanced cases High-grade cases
n % n % n % n %
n 784 784 525 170
Age at baseline (years)
Median 59 59 58 58
5th–95th percentile 51–64 51–64 51–64 51–64
Age at diagnosis (years)
Median – 66·2 66·5 67·2
5th–95th percentile – 58·2–73·9 58·5–74·2 58·8–74·3
BMI (kg/m2)
Median 26·2 26·1 26·1 26·3
5th–95th percentile 21·6–33·2 21·8–33·0 21·6–33·3 22·0–33·7
Education
Low school 311 39·7 259 33·1 174 33·1 54 33·8
Medium school 301 38·4 324 41·3 223 42·5 74 43·5
High school 172 21·9 201 25·6 128 24·4 42 24·7
Smoking status at baseline
Never 219 27·9 219 27·9 135 25·7 41 24·1
Former 289 36·9 299 38·2 200 38·1 74 43·5
Current 276 35·2 266 33·9 190 36·2 55 32·3
Smoking duration* (years)
Median 33 34 37 35
5th–95th percentile 8–48 9–49 9–49 9–49
Smoking frequency*† (g/d)
Median 20 18 20 19
5th–95th percentile 5–40 3–40 5–40 4–40
Participation in sport, at baseline
Yes 377 48·1 375 47·8 246 46·9 81 47·6
No 407 51·9 409 52·2 279 53·1 89 52·3
Baseline plasma Se biomarkers
Se (ng/ml)
Median 79·1 79·9 79·6 78·6
5th–95th percentile 61·5–105·5 60·2–104·0 60·1–104·0 58·2–97·2
Selenoprotein P (ng Se/ml)
Median 50·9‡ – 50·8 50·4
5th–95th percentile 37·3–71·1 – 37·2–69·0 38·3–65·6
Years between baseline and diagnosis (years)
Median – 8·6 8·7 9·0
5th–95th percentile – 2·2–11·9 2·1–12·0 3·2–12·0
Years between baseline and diagnosis
≤6 years – 212 27·0 141 26·9 31 18·2
>6 years – 572 73·0 384 73·1 139 80·8
PSA at baseline
≤4 ng/ml – 421 53·7 245 46·7 91 53·5
>4 ng/ml – 363 46·3 280 53·3 79 46·5
PSA, prostate-specific antigen.
* Among current and former smokers.
† Among current smokers.
‡ Only measured in cases diagnosed with advanced prostate cancer disease and their matched controls, n 525.
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For high-grade disease, a lower risk was seen according to higher
plasma selenoprotein P levels both in the minimally adjusted
(HR 0·89; 95% CI 0·79, 0·99; P=0·04) and the confounder-adjusted
model (HR 0·85; 95% CI 0·74, 0·97; P=0·01).
Higher plasma Se levels were associated with lower all-cause
mortality among prostate cancer patients. After adjustment for
potential confounders, the association was still statistically
signiﬁcant, but attenuated (HR 0·92; 95% CI 0·85, 1·00; P= 0·04)
(Table 4). Marginally, albeit not statistically signiﬁcant, lower HR
were found for prostate cancer-speciﬁc death with higher levels
of plasma Se.
For selenoprotein P (Table 5), we found no signiﬁcant
reduction in mortality among men diagnosed with advanced
prostate cancer with higher level, although the HR estimates
were below unity. We did not ﬁnd any apparent effect measure
modiﬁcation by BMI and smoking for either plasma Se or
selenoprotein P in the risk and survival analysis (all P> 0·07,
results not shown).
Finally, we examined the correlation between levels of
plasma Se and selenoprotein P. Fig 1 shows that the two
measures were closely related (correlation coefﬁcient of
0·79 (P< 0·0001)).
Discussion
In this cohort study, we found no associations between
pre-diagnostic blood Se levels and risk of total or advanced
prostate cancer in a study population with relatively low plasma
Se levels (60–105 ng/ml). Stratiﬁcation by follow-up time and
PSA levels at baseline did not affect the associations. However,
for high-grade prostate cancer, statistically signiﬁcant lower
risks were seen with higher plasma levels of both Se and
selenoprotein P. Among prostate cancer patients, there seemed
to be a slightly lower risk of overall death associated with higher
pre-diagnostic plasma Se levels.
Loss to follow-up was a minimal problem (0·02%) and
selection bias was thus of little concern. The study was also
devoid of recall bias, as the case–control study was nested
within a prospective cohort study and Se levels were measured
in pre-diagnostic blood samples.
Table 2. Association between plasma selenium concentration and prostate cancer risk for total, advanced and high-grade prostate cancer
(Odds ratios and 95% confidence intervals)
Quartiles of plasma Se* (ng/ml)
≤71·4 >71·4≤79·1 >79·1≤88·9 >88·9 Per 10 ng/ml
OR OR 95% CI OR 95% CI OR 95% CI Ptrend OR 95% CI
Total prostate cancer
Cases/controls (n) 188/198 186/193 219/197 191/196 784/784
Unadjusted 1·00 (Ref.) 0·99 0·73, 1·33 1·15 0·86, 1·52 1·00 0·74, 1·34 0·71 1·01 0·95, 1·09
Adjusted† 1·00 (Ref.) 0·97 0·71, 1·32 1·14 0·86, 1·53 0·95 0·70, 1·29 0·88 1·01 0·94, 1·08
Case baseline PSA†
Cases/controls (n) 102/109 108/110 105/105 106/97 421/421
≤4 ng/ml 1·00 (Ref.) 0·96 0·64, 1·45 0·98 0·65, 1·49 1·02 0·67, 1·57 0·84 1·01 0·91, 1·12
Cases/controls (n) 86/89 78/83 114/92 85/99 363/363
>4 ng/ml 1·00 (Ref.) 0·97 0·60, 1·58 1·28 0·84, 1·94 0·88 0·56, 1·37 0·88 0·99 0·89, 1·10
Years between blood collection and diagnosis†
Cases/controls (n) 50/54 50/53 59/54 53/51 212/212
≤6 years 1·00 (Ref.) 1·13 0·60, 2·13 1·23 0·69, 2·17 1·15 0·64, 2·01 0·81 1·02 0·89, 1·17
Cases/controls (n) 138/144 136/140 160/143 138/145 572/572
>6 years 1·00 (Ref.) 0·91 0·64, 1·30 1·12 0·79, 1·57 0·89 0·62, 1·28 0·97 1·00 0·92, 1·09
Advanced prostate cancer
Cases/controls (n) 137/130 119/129 150/127 119/139 525/525
Unadjusted 1·00 (Ref.) 0·81 0·56, 1·17 1·05 0·74, 1·49 0·75 0·52, 1·08 0·34 0·96 0·88, 1·05
Adjusted† 1·00 (Ref.) 0·80 0·54, 1·17 1·07 0·75, 1·54 0·72 0·49, 1·06 0·34 0·96 0·87, 1·05
Case baseline PSA†
Cases/controls (n) 67/62 61/66 58/57 59/60 245/245
≤4 ng/ml 1·00 (Ref.) 0·75 0·43, 1·31 0·80 0·44, 1·46 0·73 0·41, 1·31 0·56 0·96 0·83, 1·11
Cases/controls (n) 70/68 58/63 92/70 60/79 280/280
>4 ng/ml 1·00 (Ref.) 0·84 0·48, 1·47 1·25 0·78, 2·01 0·71 0·42, 1·19 0·36 0·94 0·83, 1·07
Years between blood collection and diagnosis†
Cases/controls (n) 36/31 29/35 41/37 35/38 141/141
≤6 years 1·00 (Ref.) 0·94 0·41, 2·14 1·13 0·55, 2·34 0·95 0·44, 2·04 0·94 0·99 0·83, 1·18
Cases/controls (n) 101/99 90/94 109/90 84/101 384/384
>6 years 1·00 (Ref.) 0·76 0·49, 1·19 1·08 0·70, 1·65 0·65 0·41, 1·04 0·28 0·94 0·84, 1·05
High-grade prostate cancer
Cases/controls (n) 48/38 43/40 46/47 33/45 170/170
Unadjusted 1·00 (Ref.) 0·83 0·42, 1·63 0·77 0·43, 1·41 0·58 0·30, 1·09 0·03 0·83 0·71, 0·98
Adjusted† 1·00 (Ref.) 0·62 0·30, 1·28 0·62 0·32, 1·22 0·42 0·20, 0·87 0·009 0·77 0·64, 0·94
Ref., referent values; PSA, prostate-specific antigen.
* Quartiles based on range among controls.
† Adjusted for BMI (continuous), education (low, medium, high), smoking status (never, former, current), smoking duration (continuous), smoking frequency (continuous),
participation in sport (yes/no).
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We were able to adjust for a range of potential confounding
factors, and the adjustment had only moderate inﬂuence on the
associations. However, residual confounding from unmeasured
or unknown factors associated with both Se levels and the
study outcomes cannot be ruled out. The major limitation of our
study relates to the fact that the assessment of Se concentrations
originates from only a single blood sample. This may have
introduced some exposure misclassiﬁcation, although a
single plasma Se measurement may be a valid estimate of
long-term levels according to results from a study examining
differences in two values over time (baseline and after 5 years)
(r for correlation= 0·55, P= 0·001)(35). In the mortality analyses,
we followed up each participant from his speciﬁc date of
diagnosis until death or end of follow-up, and thus studied the
association between pre-diagnostic Se levels and all-cause
mortality among men diagnosed with prostate cancer. It cannot
be excluded that pre-diagnostic Se levels are related to overall
mortality in the entire cohort, and immortal time bias could,
consequently, be an issue. Further, death related to low Se
levels occurring before a later prostate cancer diagnosis cannot
be excluded.
A recent meta-analysis reported a non-linear association
between serum/plasma Se levels and risk of prostate cancer with
a gradual decrease in risk with increasing levels in the range of
Table 3. Association between plasma selenoprotein P concentration and prostate cancer risk for advanced and high-grade prostate cancer
(Odds ratios and 95% confidence intervals)
Quartiles of plasma selenoprotein P* (ng Se/ml)
≤45·1 >45·1≤50·9 >50·9≤57·6 >57·6 Per 5 ng/ml
OR OR 95% CI OR 95% CI OR 95% CI Ptrend OR 95% CI
Advanced prostate cancer
Cases/controls (n) 135/131 129/132 146/130 115/132 525/525
Unadjusted 1·0 (Ref.) 0·92 0·65, 1·31 1·01 0·70, 1·44 0·78 0·53, 1·14 0·23 0·96 0·90, 1·03
Adjusted† 1·0 (Ref.) 0·91 0·64, 1·31 1·01 0·70, 1·47 0·78 0·53, 1·16 0·20 0·96 0·89, 1·02
Case baseline PSA†
Cases/controls (n) 66/62 63/62 61/65 55/56 245/245
≤4 ng/ml 1·0 (Ref.) 0·92 0·53, 1·59 0·80 0·45, 1·41 0·80 0·43, 1·49 0·28 0·94 0·85, 1·05
Cases/controls (n) 69/69 66/70 85/65 60/76 280/280
>4 ng/ml 1·0 (Ref.) 0·93 0·58, 1·51 1·32 0·79, 2·21 0·75 0·44, 1·27 0·34 0·96 0·88, 1·05
Years between blood collection and diagnosis†
Cases/controls (n) 38/34 31/36 39/32 33/39 141/141
≤6 years 1·0 (Ref.) 0·88 0·41, 1·90 1·28 0·60, 2·71 0·89 0·39, 2·01 0·98 1·00 0·88, 1·14
Cases/controls (n) 97/97 98/96 107/98 82/93 384/384
>6 years 1·0 (Ref.) 0·94 0·61, 1·43 0·98 0·63, 1·53 0·75 0·47, 1·21 0·17 0·94 0·87, 1·03
High-grade prostate cancer
Cases/controls (n) 46/37 47/37 45/50 32/46 170/170
Unadjusted 1·0 (Ref.) 0·94 0·50, 1·76 0·67 0·37, 1·23 0·50 0·26, 1·00 0·04 0·89 0·79, 0·99
Adjusted† 1·0 (Ref.) 1·07 0·54, 2·13 0·53 0·27, 1·05 0·44 0·20, 0·94 0·01 0·85 0·74, 0·97
Ref., referent values; PSA, prostate-specific antigen.
* Quartiles based on range among controls.
† Adjusted for BMI (continuous), education (low, medium, high), smoking status (never, former, current), smoking duration (continuous), smoking frequency (continuous),
participation in sport (yes/no).
Table 4. Association between plasma selenium concentration and all-cause and prostate cancer-specific mortality among total prostate cancer cases
(Hazard ratios (HR) and 95% confidence intervals)
Quartiles of plasma Se* (ng/ml)
≤71·7 >71·7≤79·9 >79·9≤88·7 >88·7 Per 10 ng/ml
HR HR 95% CI HR 95% CI HR 95% CI Ptrend HR 95% CI
All-cause mortality
Events (n) 88 80 68 69 305
Unadjusted 1·0 (Ref.) 1·01 0·74, 1·37 0·79 0·58, 1·37 0·76 0·55, 1·04 0·004 0·89 0·82, 0·96
Adjusted† 1·0 (Ref.) 1·06 0·77, 1·44 0·88 0·63, 1·23 0·88 0·62, 1·25 0·04 0·92 0·85, 1·00
Prostate cancer-specific mortality
Events (n) 56 55 53 48 212
Unadjusted 1·0 (Ref.) 1·14 0·78, 1·67 1·01 0·68, 1·50 0·83 0·54, 1·27 0·10 0·93 0·84, 1·01
Adjusted† 1·0 (Ref.) 1·21 0·82, 1·78 1·10 0·73, 1·63 0·93 0·60, 1·43 0·22 0·94 0·86, 1·04
Ref., referent values.
* Quartiles based on range among total cases diagnosed with prostate cancer.
† Adjusted for BMI (continuous), education (low, medium, high), smoking status (never, former, current), smoking duration (continuous), smoking frequency (continuous),
participation in sport (yes/no).
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60–170ng/ml (135ng/ml: relative risk (RR) 0·85; 95% CI 0·74,
0·97; 170ng/ml: RR 0·75; 95% CI 0·65, 0·86)(10). For advanced
prostate cancer, the meta-analysis indicated an even stronger
association within this Se range(10). Taking into account results
from randomised supplementation trials indicating a reduced risk
of prostate cancer related to Se supplementation among persons
with low baseline levels(13,15), we would expect low Se levels
to be associated with an increased risk of prostate cancer in
our low-exposure population. Although our results do not stand
in contrast to the a priori hypothesis of an inverse
association between increasing Se levels and prostate cancer risk
in a low-Se population (all lower conﬁdence limits <1·00), our
ﬁndings of neutral to slightly reduced risk estimates for total and
advanced prostate cancer do not provide strong support for the
association. Our ﬁndings on total and advanced prostate cancer
are very consistent with a previous prospective study conducted
in the EPIC cohort (mean plasma level 71 ng/ml), reporting an RR
for prostate cancer close to unity in comparison of the highest v.
lowest quintile of Se: RR 0·96; 95% CI 0·70, 1·31(36). Another
prospective study in a European population with similar Se
concentrations did, however, show a borderline signiﬁcant
association of slightly lower prostate cancer risk with higher
serum Se levels (adjusted OR 0·89; 95% CI 0·79, 1·01)(24).
However, our ﬁnding of a signiﬁcant lower risk for high-grade
prostate cancer (Gleason score≥ 8) with higher pre-diagnostic
plasma Se levels suggests that Se may have a role for the
development of aggressive disease. We have not identiﬁed pre-
vious studies evaluating the Se-prostate cancer association for
high-grade disease deﬁned as a Gleason score≥ 8.
No previous studies evaluating survival among prostate
cancer patients have been identiﬁed either. A few studies have
reported on the association between Se levels and general
mortality. A recent meta-analysis reported a marked lower
mortality related to higher Se levels (OR 0·60; 95% CI 0·39,
0·93)(37). In the US NHANES III, a non-linear association was
observed between Se status and all-cause and cancer mortality
in 13 887 participants with a mean serum Se level of approxi-
mately 125 ng/ml(16). In that study, a reduced mortality was
noted at serum Se levels up to 130 ng/ml(16).
Plasma Se reﬂects recent Se exposure(25), which could be a part
of the explanation of the mainly null associations regarding total
and advanced prostate cancer in the present study. Se content
measured in toenail clippings are expected to be a marker of Se
intake over a longer period, probably 6–12 months(18,38). Only few
studies have, however, examined associations with prostate
cancer for Se content in toenails(39–43). Although not consistently,
an overall picture of an inverse association originates from the
toenail studies(39–42). The strongest ﬁnding is reported from a
Dutch prospective study. Here, a lower risk of advanced prostate
cancer in comparison of the highest v. lowest quintile of toenail Se
content (HR 0·37; 95% CI 0·27, 0·51) was seen(39). The plasma Se
range in that study was estimated to be between 64 and 100ng/
ml(39), which is similar to the range in our study population. It is
likely that the Se content measured in toenails is less affected by
short-term ﬂuctuations in Se levels, and this biomarker may,
consequently, constitute a more relevant Se status biomarker.
Selenoprotein P is suggested to be the optimal marker of
functional Se(17), and the maximal concentration of selenoprotein
P in humans is expected to be obtained at plasma Se levels
ranging from 90 to 125ng/ml(22,23); only one ﬁfth of our study
subjects were in this range (approximately 1% had plasma Se
Table 5. Association between plasma selenoprotein P concentration and all-cause and prostate cancer-specific mortality among cases diagnosed with
advanced prostate cancer
(Hazard ratios (HR) and 95% confidence intervals)
Quartiles of plasma selenoprotein P* (Se ng/ml)
≤44·7 >44·7≤50·8 >50·8≤56·3 >56·3 Per 5 ng/ml
HR HR 95% CI HR 95% CI HR 95% CI Ptrend HR 95% CI
All-cause mortality
Events (n) 70 63 69 60 262
Unadjusted 1·0 (Ref.) 0·93 0·66, 1·31 1·07 0·76, 1·49 0·83 0·59, 1·17 0·21 0·96 0·90, 1·02
Adjusted† 1·0 (Ref.) 0·99 0·70, 1·40 1·15 0·82, 1·62 0·94 0·66, 1·33 0·60 0·98 0·92, 1·05
Prostate cancer-specific mortality
Events (n) 48 48 57 43 196
Unadjusted 1·0 (Ref.) 1·02 0·68, 1·53 1·28 0·87, 1·89 0·86 0·57, 1·30 0·64 0·98 0·92, 1·06
Adjusted† 1·0 (Ref.) 1·05 0·69, 1·58 1·34 0·91, 1·98 0·92 0·61, 1·40 0·91 1·00 0·93, 1·07
Ref., referent values.
* Quartiles based on range among cases diagnosed with advanced prostate cancer.
† Adjusted for BMI (continuous), education (low, medium, high), smoking status (never, former, current), smoking duration (continuous), smoking frequency (continuous),
participation in sport (yes/no).
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Fig. 1. Correlation between plasma selenoprotein P and plasma Se
concentrations in 525 controls (Pearson’s correlation, r 0·79, P< 0·0001).
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levels> 125ng/ml). Therefore, we also included selenoprotein P
as a biomarker of Se status. We did not ﬁnd an association
between selenoprotein P and advanced prostate cancer risk,
which is in agreement with another study based on a European
population(24). For high-grade disease, we did ﬁnd a signiﬁcant
association of lower risk for higher selenoprotein P levels. The
estimate was, though, in the same magnitude as seen for plasma
Se and did not indicate that selenoprotein P is superior to plasma
Se as Se biomarker.
Selenoprotein P has been found to be reduced in prostate
tumours(44), and lower levels have also been observed in
prostate cancer patients(45). Because prostate cancers typically
progress slowly and the disease has a long latency(46), the levels of
selenoprotein P and plasma Se might have been affected by the
growing tumour already at baseline. We stratiﬁed the analyses
according to time from baseline to diagnosis (≤6, >6 years), but
the associations were almost similar for the two follow-up periods.
Stratifying the analyses according to time from baseline to
diagnosis of 10 years gave similar results (results not shown). It is
still possible, though, that the length of follow-up was too short to
fully evaluate this hypothesis.
We also evaluated the association between Se levels and
prostate cancer risk stratiﬁed by baseline PSA levels and found
similar associations in the two groups (≤4 v. >4ng/ml). We
expected a stronger association for cases with PSA levels >4ng/ml,
because of the hypothesis that Se may have a role in delaying
prostate cancer tumour progression. A previous prospective study
reported a stronger association of Se and prostate cancer risk
among men with higher baseline PSA levels(35), and the NPC trial
showed a reduced incidence of prostate cancer after Se supple-
mentation among men with baseline PSA levels ≤4ng/ml(15).
The range of plasma Se in the present study population was, as
expected, similar to what has been reported from other European
populations (mean 70–80ng/ml)(36), but lower than in studies
conducted in US populations (median 105–140ng/ml)(10).
Furthermore, in our study population, we observed a strong
correlation between plasma Se and selenoprotein P, indicating that
both Se measures are relevant to use as objective markers of Se
exposure in a low-Se population. Our ﬁnding of a strong correlation
is consistent with ﬁndings in other European populations in which
correlations between 0·60 and 0·88 have been reported(24,47,48).
Our study did not conﬁrm higher blood Se or selenoprotein P
levels to be associated with a reduced risk of total or advanced
prostate cancer in a low-Se population. We did, however, ﬁnd
higher levels of both Se biomarkers to be associated with a
lower risk of high-grade disease. Higher plasma Se levels were
associated with a slightly reduced all-cause mortality among
prostate cancer patients, whereas no association was found for
prostate cancer-speciﬁc mortality.
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